History of aspirin Hermann Hildebrandt). In 1894, the young chemist Felix Hoffmann joined the pharmaceutical group. Dreser, Eichengrün and Hoffmann would be the key figures in the development of acetylsalicylic acid as the drug Aspirin (though their respective roles have been the subject of some contention). In 1897, Hoffmann started working to find a less irritating substitute for salicylic acid. It is generally accepted that he turned to this idea because his father was suffering the side effects of taking sodium salicylate for rheumatism. In 1853, Charles Frédéric Gerhardt had published the first methods to prepare acetylsalicylic acid. In the course of his
Hyodeoxycholic acid animal study determined that oral administration of HDCA leads to a decrease in LDL-cholesterol concentration, a strong stimulation of hepatic cholesterol biosynthesis and an excessive loss of cholesterol in feces. Unlike ursodeoxycholic acid, which is an approved drug for the treatment of gallstones, HDCA is not marketed for any medical condition. In supramolecular chemistry a molecular tweezer based on a hyodeoxycholic acid showed a high selectivity the towards the fluorine radical. Hyodeoxycholic acid Hyodeoxycholic acid, also known as 3α,6α-Dihydroxy-5β-cholan-24-oic acid or HDCA, is a secondary bile acid, one of the metabolic byproducts of intestinal bacteria. It differs from deoxycholic acid